The antigens gp100 and tyrosinase are also expressed by melanocytes and can lead to cutaneous adverse events as one could see in the IMCgp100 trial with the occurrence of 83% rash, 69% pruritus, 25% erythema, 21% skin exfoliation, 20% hair color changes, and 16% vitiligo (36). The gene discussed is PMEL; the disease is vitiligo.